The question of reversibility is also relevant to therapies aiming to activate SARM1 for neuroablation to treat conditions such as spasticity, dystonia and neuropathic pain, because permanent SARM1 activation in these conditions could lead to unwanted effects and lasting disability. This evidence concerns the gene SARM1 and Dystonia.